Attention
This section of the web-site contains information on medicines, advertising of which is not foreseen by the legislation. Information in this section is intended for reference only, has exclusively scientific and informative character and should not be treated as advertising information for a wide range of people. According to the current legislation, access to this information is granted to medical and pharmaceutical employees. Please confirm that you are a medical or pharmaceutical employee.

ISLA-Mint® & ISLA-Moos®

Hoarseness or huskiness and even loss of voice are the states that everyone can face. Everyone needs a voice! But, how to get it back quickly, in such a case?

ISLA-Mint®and ISLA-Moos® are Icelandic moss based pastilles. They have a protective (i.e. they envelop and moisturize the mucous), antimicrobial, anti-inflammatory and immunomodulatory effects.

Due to these properties, ISLA-Mint® and ISLA-Moos® pastilles envelop and humidify the respiratory tract, remove inflammation, eliminate huskiness, itching and burning, thereby helping to restore hoarse, husky or lost voice.

Unlike lozenges, pastilles do not contain sugar and cannot injure gums and palate mucosa. ISLA-Mint® and Isla-moos are approved for use in adults and children from 4 and are indicated in laryngitis, hoarseness, huskiness and to people, who face high voice load or work in adverse climatic conditions (cold, heat, dust, etc.). ISLA-Mint® and Isla Moos® are helpful in dry irritating cough, to include of allergic origin.

ISLA-Mint® & ISLA-Moos® – applicable in hoarseness, huskiness and dry irritating cough

Isla Mint pastilles: produced by Engelhard Arzneimittel GmbH & Co. KG (Germany), Marketing Authorization No. UA/2187/01/01 dd. 21.01.2010; Isla Moos pastilles: produced by Engelhard Arzneimittel GmbH& Co. KG (Germany), Marketing Authorization No. UA/2188/01/01 dd. 15.02.2010.

Drug advertising. Read instructions carefully and consult a doctor before use. Keep out of the reach of children.

Self-medication can be harmful to your health

Cetraria islandica    

Engelhard Arzneimittel R02A A20

Against husky voice, hoarseness, and dry, irritative cough

ISLA-Mint formulation:
Pastilles, 100 mg, No. 30, 10 pastilles in a blister, 3 blisters in a cardboard box

Composition:
Aqueous extract of Iceland moss (2-4:1) 100 mg

Additional substances: Sorbite solution, 70%,  not crystallizing, aspartame, gum arabic, peppermint oil, copper chlorophyll complexes, light mineral oil, purified water.
1 pastille contains 0.385 g of  carbohydrates that is equivalent 0.03 bread unit.

ISLA-Moos formulation:
Pastille 80 mg, No. 30, 10 pastilles in a blister, 3 blisters in a cardboard box

Composition:
Aqueous extract of Iceland moss (0.4-0.8:1) 80 mg

Additional substances: Gum arabic, sucrose, light mineral oil, ammonia caramel, purified water.
1 pastille contains 424 mg of sucrose that is equivalent to 0.035 bread unit.

Pharmacotherapeutic group: Medication used for treatment of throat diseases. ATC code: R02A A20.

Indications:

  • Cough including that under bronchitis; hoarseness (laryngitis, pharyngitis); butylamine (as additional agent);
  • Hard stress for vocal cords (singers, teachers, lecturers);
  • mucous membrane dryness in dry atmosphere of living or office rooms in heating periods along with restricted nasal breathing of when playing sports.

Contraindications:
In case of phenylketonuria, it is necessary to take into consideration that the medication contains sweet substance, aspartame. Intolerance to fructose. Hypersensitivity to any medication component.

Adverse effects:
In rare cases, allergic reactions may be observed.
Very rarely, in patients with high sensitivity the medication, containing sorbite may cause purgative effect.

Interactions: So far, no interactions have been observed.

Overdosage: No reports about overdosages.

Storage requirements: To be kept at up to 25°C, in a dry place inaccessible for children.

Shelf life: 4 years.

Sell condition: over the counter.

Isla-mint and Isla-Moos medications contain extract from a drug plant, Cetraria Islandica (Iceland moss) which was well known yet in the times of ancient civilizations because of its beneficial therapeutic effect in cases of respiratory tract inflammation diseases.

Treatment effect of  the Isla-Mint and Isla-Moos medications in cases of respiratory tract catarrhal diseases is based, mainly, on antimicrobial activity and immunostimulating properties of the plant extract they contain, which has been proved by results of scientific researches. Since Isla-Mint and Isla-Moos medications have protective properties, too, they may be used also for prophylaxis – for example, in case of high respiratory tract sensitivity or high respiratory load (including sports).
Polysaccharides contained in the medication cover mucous membranes of air channels efficiently protecting them from adverse external factors and various types of irritants.

Where there is a risk of catching cold, prophylactic use of Isla-Mint and Isla-Moos medications that can protect mucous membranes may reduce respiratory tact susceptibility to various types of infections. The medication cause no stomach irritation.

For children aged 4 to 12 years: 1 pastille very 2 h (up to 6 pastilles daily), for adults and children aged over 12: 1 pastille every hour (up to 12 pastilles daily), letting them to slowly dissolve in one’s mouth.

ISLA-Mint and ISLA-Moos are well tolerated medications, so they may be used, with no risk, for long time.

Besides, even after disappearing of the disease symptoms, ISLA-Mint and ISLA-Moos shall be intaken for some time in order to reach stable therapeutic effect.

If in 4 or 5 days stable disease symptoms do not enhance or, on the contrary, they are worsening, short breath, fever, or purulent and bloody sputum appear, it Is necessary to consult a doctor immediately.

Plant extracts contained in ISLA-Mint and ISLA-Moos may sometimes cause deviations in color and taste of this medication which, however, has no influence on its therapeutic effect.

ISLA-Mint and ISLA-Moos contain no sugar, so they may be administered to patients with diabetes mellitus. 1 pastille is equivalent to 0.03 BU = 0.385 g of carbohydrates.

Intaking in a period of pregnancy or lactation: No reports on negative effect of the medication in periods of pregnancy or lactation. No special research was carried for this category of patients, so it is reasonable to assess the risk/advantage proportion before using the medication.

Effecting  reaction rate when driving a vehicle or working with other mechanisms: Intaking the medication according the instruction on its medical use is not supposed to bring any negative results.

Children: The medication is aimed for children aged over 4 since pastilles shall be held in one’s mouth letting them dissolve slowly.

If the disease symptoms remaining for long time as well as in case of appearing short breath, fever, or purulent and bloody sputum, it is necessary to consult a doctor immediately.

0

Ask a question